← Back to Home

Gazyva Granted FDA Priority Review, Potentially Ushering in the First Approved Treatment for Membranous Nephropathy

For patients with primary membranous nephropathy, this review is not simply a regulatory milestone, but a treatment gap long dependent on immunosuppression and kidney care that is finally approaching a clear decision.

By SURL BioNews

Primary membranous nephropathy is a chronic autoimmune kidney disease in which the glomerular filtration barrier is attacked by the immune system, often presenting with heavy proteinuria, edema, and gradual impairment of kidney function. For many patients, the disease course is long and recurrent; however, in the United States and Europe, there are currently still no treatments specifically approved by the FDA or EMA. For that reason, the FDA Priority Review granted to Roche’s anti-CD20 monoclonal antibody Gazyva/Gazyvaro is significant not only because it accelerates the review timeline, but also because this field, where new drug options are scarce, may see its first formally approved therapy.

Roche said on July 15 that the U.S. FDA has accepted and granted Priority Review to a supplemental biologics license application for obinutuzumab in adults with primary membranous nephropathy. Its U.S. member company Genentech also announced the same development the previous day and noted that the FDA had previously granted Breakthrough Therapy Designation for this indication. Under the current timeline, the FDA is expected to make a review decision by November 2026.

The application is based mainly on results from the Phase 3 MAJESTY trial. According to data released by Roche and Genentech, at week 104, 36.9% of adult patients treated with Gazyva achieved complete remission, compared with 5.7% in the active comparator tacrolimus group. Complete remission generally means that proteinuria has improved substantially and approached the normal range, a highly important endpoint in the treatment of this type of kidney disease; however, full efficacy details, secondary endpoints, and outcomes in different patient subgroups still require more complete trial publications or review documents.

ClinicalTrials.gov registration data show that MAJESTY is NCT04629248, sponsored by Hoffmann-La Roche, and is a Phase 3, randomized, open-label, active-controlled trial comparing the efficacy and safety of obinutuzumab and tacrolimus in adults with primary membranous nephropathy. Enrollment is listed as 142 participants, the primary completion date is December 22, 2025, and the overall study is estimated to continue until December 21, 2027.

Gazyva/Gazyvaro is not a new drug. It is a CD20-targeting B-cell medicine that has already been used to treat certain hematologic cancers; moving it into autoimmune kidney disease reflects a renewed focus on disease mechanisms. Primary membranous nephropathy is closely associated with autoantibody production. If B-cell depletion can reduce immune attack, it may theoretically allow proteinuria to remit and slow deterioration of kidney function.

Safety remains an issue that must be carefully weighed before this type of therapy enters routine nephrology practice. Genentech said no new safety signals were observed in MAJESTY; however, when patients receive B-cell-depleting treatment, clinicians generally still need to assess infection risk, immune status, and comorbid conditions. Because the trial was open-label and the participant population was not large, how regulators interpret the strength of efficacy, long-term risks, and generalizability will affect the final label scope.

If the FDA approves it by November, Gazyva could become the first U.S.-approved treatment option for primary membranous nephropathy. Genentech also said MAJESTY data are being submitted to other global regulators, including the EMA. For patients and physicians, the next key questions are not only whether it will be approved, but also how the eligible population will be defined after approval, when treatment should be initiated, and how to balance effective immune control with long-term safety.

References

  1. Roche
  2. Genentech
  3. ClinicalTrials.gov